 Sherwin Chan
Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 5 | 2022 | 50 | 2.940 |
Why?
| | Magnetic Resonance Imaging | 11 | 2024 | 122 | 2.600 |
Why?
| | Hepatic Veno-Occlusive Disease | 4 | 2020 | 5 | 2.250 |
Why?
| | Ultrasonography, Doppler | 5 | 2020 | 9 | 2.160 |
Why?
| | Humans | 53 | 2024 | 6929 | 2.100 |
Why?
| | Enterocolitis, Necrotizing | 6 | 2022 | 67 | 1.830 |
Why?
| | Vascular Diseases | 2 | 2023 | 8 | 1.630 |
Why?
| | Magnetic Resonance Angiography | 2 | 2022 | 9 | 1.630 |
Why?
| | Radiology | 3 | 2020 | 3 | 1.540 |
Why?
| | Societies, Medical | 14 | 2024 | 50 | 1.530 |
Why?
| | Hepatic Artery | 2 | 2023 | 7 | 1.470 |
Why?
| | Child | 29 | 2024 | 3348 | 1.470 |
Why?
| | Ultrasonography | 8 | 2022 | 49 | 1.410 |
Why?
| | Contrast Media | 6 | 2022 | 25 | 1.360 |
Why?
| | Decision Support Systems, Clinical | 2 | 2019 | 17 | 1.330 |
Why?
| | Infant, Newborn, Diseases | 5 | 2022 | 30 | 1.330 |
Why?
| | Elasticity Imaging Techniques | 2 | 2018 | 7 | 1.280 |
Why?
| | Pediatrics | 2 | 2019 | 183 | 1.120 |
Why?
| | Evidence-Based Medicine | 11 | 2024 | 45 | 1.090 |
Why?
| | Foreign Bodies | 2 | 2021 | 23 | 0.990 |
Why?
| | Retrospective Studies | 12 | 2024 | 1337 | 0.990 |
Why?
| | Surface Plasmon Resonance | 2 | 2022 | 3 | 0.930 |
Why?
| | Gastric Bypass | 1 | 2023 | 8 | 0.910 |
Why?
| | Infant, Newborn | 13 | 2024 | 826 | 0.910 |
Why?
| | Gastrostomy | 1 | 2023 | 67 | 0.850 |
Why?
| | Software | 2 | 2019 | 26 | 0.830 |
Why?
| | Gadolinium | 2 | 2021 | 3 | 0.830 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2022 | 38 | 0.830 |
Why?
| | Tomography, X-Ray Computed | 6 | 2022 | 130 | 0.810 |
Why?
| | Severity of Illness Index | 5 | 2020 | 148 | 0.800 |
Why?
| | United States | 14 | 2024 | 670 | 0.770 |
Why?
| | Arthritis, Infectious | 2 | 2022 | 2 | 0.740 |
Why?
| | Male | 14 | 2024 | 3367 | 0.720 |
Why?
| | Infant | 13 | 2024 | 1449 | 0.680 |
Why?
| | Postoperative Complications | 2 | 2020 | 202 | 0.680 |
Why?
| | Female | 14 | 2024 | 3534 | 0.660 |
Why?
| | Liver Diseases | 1 | 2018 | 17 | 0.650 |
Why?
| | Fracture Healing | 1 | 2018 | 4 | 0.650 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 2 | 0.650 |
Why?
| | Fractures, Bone | 1 | 2018 | 35 | 0.630 |
Why?
| | Sensitivity and Specificity | 5 | 2018 | 151 | 0.620 |
Why?
| | Fused Kidney | 1 | 2017 | 1 | 0.610 |
Why?
| | Reproducibility of Results | 7 | 2024 | 198 | 0.610 |
Why?
| | Hospitals, Pediatric | 1 | 2019 | 186 | 0.600 |
Why?
| | Radiography | 4 | 2023 | 49 | 0.600 |
Why?
| | Diagnostic Imaging | 8 | 2024 | 16 | 0.550 |
Why?
| | Liver Transplantation | 1 | 2016 | 47 | 0.540 |
Why?
| | Lyme Disease | 1 | 2015 | 1 | 0.530 |
Why?
| | Scimitar Syndrome | 1 | 2015 | 1 | 0.520 |
Why?
| | Tetralogy of Fallot | 1 | 2015 | 2 | 0.520 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2015 | 6 | 0.520 |
Why?
| | Heart Ventricles | 1 | 2015 | 55 | 0.490 |
Why?
| | Arterial Occlusive Diseases | 1 | 2013 | 4 | 0.460 |
Why?
| | Models, Cardiovascular | 1 | 2013 | 5 | 0.460 |
Why?
| | Arteries | 1 | 2013 | 3 | 0.460 |
Why?
| | Adolescent | 9 | 2024 | 2183 | 0.460 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2013 | 22 | 0.450 |
Why?
| | Child, Preschool | 7 | 2024 | 1562 | 0.450 |
Why?
| | Outpatients | 2 | 2022 | 28 | 0.430 |
Why?
| | Phlebography | 2 | 2022 | 7 | 0.410 |
Why?
| | Adult | 5 | 2023 | 1199 | 0.410 |
Why?
| | Lung Neoplasms | 2 | 2022 | 23 | 0.400 |
Why?
| | Hand | 2 | 2010 | 3 | 0.380 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2021 | 20 | 0.380 |
Why?
| | Constriction, Pathologic | 2 | 2023 | 21 | 0.370 |
Why?
| | Obesity | 2 | 2021 | 124 | 0.360 |
Why?
| | Young Adult | 4 | 2021 | 641 | 0.330 |
Why?
| | Liver | 2 | 2021 | 130 | 0.330 |
Why?
| | Prospective Studies | 2 | 2022 | 547 | 0.320 |
Why?
| | Arm | 2 | 2006 | 3 | 0.310 |
Why?
| | Joints | 1 | 2006 | 3 | 0.290 |
Why?
| | Muscle, Skeletal | 1 | 2006 | 13 | 0.290 |
Why?
| | Algorithms | 2 | 2023 | 108 | 0.280 |
Why?
| | Early Diagnosis | 3 | 2020 | 17 | 0.270 |
Why?
| | Feasibility Studies | 2 | 2022 | 59 | 0.260 |
Why?
| | Anthropometry | 2 | 2020 | 16 | 0.260 |
Why?
| | Magnets | 1 | 2014 | 2 | 0.250 |
Why?
| | Gastrointestinal Tract | 1 | 2014 | 7 | 0.250 |
Why?
| | Image Enhancement | 1 | 2014 | 14 | 0.250 |
Why?
| | Pulmonary Blastoma | 2 | 2022 | 5 | 0.250 |
Why?
| | Vascular Malformations | 1 | 2024 | 3 | 0.240 |
Why?
| | Urinary Tract Infections | 1 | 2024 | 21 | 0.240 |
Why?
| | Movement | 3 | 2010 | 8 | 0.230 |
Why?
| | Motor Cortex | 3 | 2010 | 7 | 0.230 |
Why?
| | Coronary Artery Disease | 1 | 2023 | 10 | 0.230 |
Why?
| | Diagnosis, Differential | 5 | 2023 | 78 | 0.230 |
Why?
| | Heart Diseases | 1 | 2023 | 19 | 0.230 |
Why?
| | Fluoroscopy | 1 | 2023 | 20 | 0.230 |
Why?
| | Machine Learning | 1 | 2023 | 17 | 0.220 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 333 | 0.220 |
Why?
| | Transplant Recipients | 1 | 2022 | 9 | 0.220 |
Why?
| | Medical Oncology | 1 | 2022 | 18 | 0.220 |
Why?
| | Rhabdomyoma | 1 | 2022 | 1 | 0.220 |
Why?
| | Tuberous Sclerosis | 1 | 2022 | 4 | 0.220 |
Why?
| | Heart Neoplasms | 1 | 2022 | 2 | 0.220 |
Why?
| | Health Care Costs | 1 | 2022 | 31 | 0.220 |
Why?
| | Clinical Competence | 1 | 2022 | 30 | 0.210 |
Why?
| | User-Computer Interface | 3 | 2019 | 11 | 0.210 |
Why?
| | Osteomyelitis | 1 | 2022 | 8 | 0.210 |
Why?
| | Lung Diseases | 1 | 2022 | 23 | 0.210 |
Why?
| | Crohn Disease | 1 | 2022 | 25 | 0.210 |
Why?
| | Fetal Diseases | 1 | 2022 | 5 | 0.210 |
Why?
| | Body Surface Area | 1 | 2021 | 11 | 0.200 |
Why?
| | Nephrogenic Fibrosing Dermopathy | 1 | 2021 | 1 | 0.200 |
Why?
| | Radio Waves | 1 | 2021 | 3 | 0.200 |
Why?
| | Life Style | 1 | 2021 | 24 | 0.190 |
Why?
| | End Stage Liver Disease | 1 | 2021 | 2 | 0.190 |
Why?
| | Weight Loss | 1 | 2021 | 36 | 0.190 |
Why?
| | Hydronephrosis | 1 | 2020 | 2 | 0.190 |
Why?
| | Overweight | 1 | 2021 | 50 | 0.190 |
Why?
| | Pilot Projects | 1 | 2021 | 114 | 0.190 |
Why?
| | Patient Selection | 1 | 2021 | 34 | 0.190 |
Why?
| | Sacrum | 1 | 2020 | 2 | 0.190 |
Why?
| | Fecal Incontinence | 1 | 2020 | 20 | 0.180 |
Why?
| | Pneumonia | 1 | 2020 | 32 | 0.180 |
Why?
| | Hip Dislocation, Congenital | 1 | 2019 | 1 | 0.170 |
Why?
| | Meaningful Use | 1 | 2019 | 2 | 0.170 |
Why?
| | Medicare | 1 | 2019 | 4 | 0.170 |
Why?
| | Brain | 3 | 2022 | 79 | 0.170 |
Why?
| | Leg | 1 | 2018 | 4 | 0.170 |
Why?
| | Bone Diseases | 1 | 2018 | 4 | 0.170 |
Why?
| | Movement Disorders | 1 | 2018 | 4 | 0.160 |
Why?
| | Psychomotor Performance | 2 | 2010 | 5 | 0.160 |
Why?
| | Radiographic Image Enhancement | 1 | 2018 | 3 | 0.160 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2018 | 17 | 0.160 |
Why?
| | Cost-Benefit Analysis | 1 | 2018 | 27 | 0.160 |
Why?
| | Hematuria | 1 | 2018 | 7 | 0.160 |
Why?
| | Pediatric Obesity | 1 | 2021 | 130 | 0.160 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 85 | 0.160 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 102 | 0.150 |
Why?
| | Kidney Function Tests | 1 | 2017 | 22 | 0.150 |
Why?
| | Appendicitis | 1 | 2019 | 119 | 0.140 |
Why?
| | Brain Mapping | 2 | 2007 | 10 | 0.140 |
Why?
| | Pregnancy | 3 | 2022 | 212 | 0.140 |
Why?
| | Borrelia burgdorferi | 1 | 2015 | 1 | 0.130 |
Why?
| | Hip Joint | 1 | 2015 | 4 | 0.130 |
Why?
| | Autistic Disorder | 1 | 2015 | 13 | 0.130 |
Why?
| | Middle Aged | 1 | 2016 | 645 | 0.130 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2014 | 4 | 0.120 |
Why?
| | Pelvic Bones | 1 | 2014 | 9 | 0.120 |
Why?
| | Granuloma | 1 | 2014 | 4 | 0.120 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2014 | 5 | 0.120 |
Why?
| | Enoxaparin | 1 | 2014 | 3 | 0.120 |
Why?
| | Vascular Resistance | 1 | 2013 | 4 | 0.120 |
Why?
| | Blood Flow Velocity | 1 | 2013 | 8 | 0.120 |
Why?
| | Biomechanical Phenomena | 3 | 2010 | 8 | 0.110 |
Why?
| | Animals | 4 | 2010 | 741 | 0.110 |
Why?
| | Gestational Age | 2 | 2022 | 64 | 0.100 |
Why?
| | Macaca mulatta | 2 | 2010 | 22 | 0.090 |
Why?
| | Treatment Outcome | 2 | 2020 | 649 | 0.090 |
Why?
| | Prognosis | 2 | 2021 | 216 | 0.090 |
Why?
| | Rotation | 1 | 2010 | 5 | 0.090 |
Why?
| | Risk Factors | 2 | 2021 | 490 | 0.080 |
Why?
| | Motion Perception | 1 | 2007 | 1 | 0.070 |
Why?
| | Space Perception | 1 | 2007 | 2 | 0.070 |
Why?
| | Infrared Rays | 1 | 2006 | 1 | 0.070 |
Why?
| | Shoulder Joint | 1 | 2006 | 1 | 0.070 |
Why?
| | Wrist Joint | 1 | 2006 | 1 | 0.070 |
Why?
| | Elbow Joint | 1 | 2006 | 2 | 0.070 |
Why?
| | Models, Anatomic | 1 | 2006 | 2 | 0.070 |
Why?
| | Muscle Contraction | 1 | 2006 | 3 | 0.070 |
Why?
| | Kinetics | 1 | 2006 | 34 | 0.070 |
Why?
| | Computer Simulation | 1 | 2006 | 31 | 0.070 |
Why?
| | Models, Statistical | 1 | 2006 | 29 | 0.070 |
Why?
| | Visual Perception | 1 | 2006 | 1 | 0.070 |
Why?
| | Evoked Potentials, Motor | 1 | 2006 | 1 | 0.070 |
Why?
| | Task Performance and Analysis | 1 | 2006 | 3 | 0.070 |
Why?
| | False Negative Reactions | 1 | 2014 | 10 | 0.060 |
Why?
| | Device Removal | 1 | 2014 | 18 | 0.060 |
Why?
| | Cerebral Ventricles | 1 | 2024 | 2 | 0.060 |
Why?
| | Vascular Neoplasms | 1 | 2024 | 1 | 0.060 |
Why?
| | Hemangioma | 1 | 2024 | 3 | 0.060 |
Why?
| | Soft Tissue Neoplasms | 1 | 2024 | 7 | 0.060 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 104 | 0.060 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2022 | 11 | 0.060 |
Why?
| | Hospitals | 1 | 2022 | 36 | 0.050 |
Why?
| | Skeleton | 1 | 2022 | 1 | 0.050 |
Why?
| | Birth Weight | 1 | 2022 | 28 | 0.050 |
Why?
| | Lung | 1 | 2022 | 66 | 0.050 |
Why?
| | Case-Control Studies | 1 | 2022 | 216 | 0.050 |
Why?
| | Hepatobiliary Elimination | 1 | 2021 | 2 | 0.050 |
Why?
| | Datasets as Topic | 1 | 2021 | 7 | 0.050 |
Why?
| | Organ Size | 1 | 2021 | 14 | 0.050 |
Why?
| | Metabolic Clearance Rate | 1 | 2021 | 18 | 0.050 |
Why?
| | Injections, Intravenous | 1 | 2021 | 14 | 0.050 |
Why?
| | Ribonuclease III | 1 | 2021 | 2 | 0.050 |
Why?
| | DEAD-box RNA Helicases | 1 | 2021 | 4 | 0.050 |
Why?
| | Prenatal Diagnosis | 1 | 2021 | 14 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2021 | 19 | 0.050 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2021 | 7 | 0.050 |
Why?
| | Infant, Premature | 1 | 2022 | 86 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 44 | 0.050 |
Why?
| | Vomiting | 1 | 2020 | 23 | 0.050 |
Why?
| | Disease Progression | 1 | 2021 | 110 | 0.050 |
Why?
| | Observer Variation | 1 | 2020 | 14 | 0.050 |
Why?
| | Age Factors | 1 | 2021 | 211 | 0.050 |
Why?
| | Family | 1 | 2020 | 27 | 0.050 |
Why?
| | Cohort Studies | 1 | 2021 | 281 | 0.050 |
Why?
| | Cholagogues and Choleretics | 1 | 2019 | 1 | 0.040 |
Why?
| | Polydeoxyribonucleotides | 1 | 2019 | 1 | 0.040 |
Why?
| | Ursodeoxycholic Acid | 1 | 2019 | 1 | 0.040 |
Why?
| | Fibrinolytic Agents | 1 | 2019 | 5 | 0.040 |
Why?
| | Bilirubin | 1 | 2019 | 25 | 0.040 |
Why?
| | Mutation | 1 | 2021 | 213 | 0.040 |
Why?
| | Risk Assessment | 1 | 2020 | 136 | 0.040 |
Why?
| | Length of Stay | 1 | 2021 | 243 | 0.040 |
Why?
| | Biomarkers | 1 | 2019 | 132 | 0.040 |
Why?
| | Disease Management | 1 | 2019 | 36 | 0.040 |
Why?
| | Motor Neurons | 2 | 2010 | 3 | 0.040 |
Why?
| | Action Potentials | 2 | 2010 | 5 | 0.040 |
Why?
| | Models, Neurological | 2 | 2010 | 5 | 0.040 |
Why?
| | Acute Disease | 1 | 2018 | 77 | 0.040 |
Why?
| | Multimodal Imaging | 1 | 2014 | 2 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2014 | 3 | 0.030 |
Why?
| | Lymphoma | 1 | 2014 | 9 | 0.030 |
Why?
| | Injections | 1 | 2014 | 5 | 0.030 |
Why?
| | Reaction Time | 1 | 2007 | 1 | 0.020 |
Why?
| | Macaca fascicularis | 1 | 2007 | 2 | 0.020 |
Why?
| | Functional Laterality | 1 | 2007 | 3 | 0.020 |
Why?
| | Macaca | 1 | 2006 | 2 | 0.020 |
Why?
| | Haplorhini | 1 | 2006 | 3 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|